SYDNEY, May 4, 2023 – George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing […]
Read MoreA deeper understanding of disease mechanisms will help address a growing global problem. Chronic kidney disease (CKD) is a global health crisis with an estimated 850 million people affected worldwide. Rising faster than all non-infectious diseases including cardiovascular disease, CKD is 20 times more prevalent than cancer. Most people don’t even realize their kidneys are […]
Read MoreAs part of our Corporate Social Responsibility (CSR) initiative, George Clinical India in collaboration with Trinity Care Foundation (an NGO) intends to distribute Hearing Aids for Hearing Impaired Children & Assistive Aids for Children with Disabilities from the marginalized sections of the community. Hearing loss can affect a child’s ability to develop communication, language, and […]
Read MoreFierce Pharma recently reported that GSK’s oral anemia drug, Jesduvroq, has scored partial FDA approval after two rivals previously suffered rejections. George Clinical’s global and national scientific leadership helped move the breakthrough CKD anemia treatment forward via the collaboration between the organization’s exceptional kidney and metabolic scientific leadership network and GSK. The network provided continuity, […]
Read MoreSYDNEY, December 9, 2022 – George Clinical announces that it has entered into a sale agreement with Hillhouse, a global investment firm with deep experience in partnering with and supporting healthcare businesses. The transaction will allow George Clinical to continue a path of rapid global expansion, leadership in Asia-Pacific clinical research services, and will provide considerable […]
Read More
George Clinical Represented at AusBiotech 2022 Conference in Perth. Australia is a world-leading location for the life sciences and has been ranked among the top five in biotechnology innovation for the third consecutive year. AusBiotech is Australia’s life sciences organization, working on behalf of a well-connected network of over 3,000 members for more than 35 […]
Read MoreOVERLAND PARK, Ks., October 25, 2022 – George Clinical, in close collaboration with The George Institute for Global Health, has recently announced the recruitment of more than 5,000 patients in its ground-breaking, first of its kind, Global Kidney Patient Trials Network (GKPTN) which will accelerate treatments for kidney disease. The concept for the GKPTN is […]
Read MoreBEIJING, September 7, 2022 – George Clinical, a global clinical research organization with an extensive presence throughout the Asia-Pacific region, continues to expand the organization’s team in China with the addition of Helen Xu as Project Director and Cell Gene Therapy Head. She will be based in Beijing and joins a rapidly growing team responsible […]
Read MoreThat leaves 80% of mBC patients with fewer treatment options. However, research has shown that 55%-60% of these actually express low levels of HER2, and this is the category that Destiny-04 targeted, demonstrating that the legacy cutoff point to determine HER2 positivity can now be extended. These results establish HER2-low metastatic breast cancer as a […]
Read MoreGillian Ryan joined George Clinical in the spring of 2021 with over 20 years of experience in the pharmaceutical industry including experience working in, and with, large pharma companies and clinical research organizations, across all phases of drug development and many therapeutic areas. Gillian’s experience spans both project operations and medical affairs and she holds […]
Read More
